Recent Scientific Publications

Journal Articles

1. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 2008 May;94(4):315-23.
   View abstract >
2. Schlenke P, Hervig T, Isola H, et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008 Apr;48(4):697-705.
   View abstract >
3. Jacobs MR, Good CE, Lazarus HM, Yomtovian RA. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis. 2008 Apr 15;46(8):1214-20.
   View abstract >
4. Murphy WG, Foley M, Doherty C, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang. 2008 Apr 2 (Epub ahead of print).
   View abstract >
5. Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev. 2008 Apr;22(2):97-102.
   View abstract >
6. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 Mar 13 (Epub ahead of print).
   View abstract >
7. Tynngård N, Johansson BM, Lindahl TL, et al. Effects of INTERCEPT pathogen inactivation on platelet function as analysed by free oscillation rheometry. Transfus Apher Sci. 2008 Feb;38(1):85-8.
   View abstract >
8. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008 Jan;48(1):108-17
   View abstract >

Conference Abstracts

XXXth International Congress of the International Society of Blood Transfusion (ISBT)
June 7–12, 2008 | Macao, China    

1. JP Cazenave. European View About Pathogen Inactivation in Labile Blood Products.
   Vox Sang 2008;95(Suppl 1):8
2. JA Cancelas, L Dumont, L Herschel, J Roger, N Rugg, G Garratty, P Arndt, M Propst, L Corash, D Sundin, J AuBuchon. A Randomized, Controlled, 2-Period Crossover Study of Recovery and Lifespan of Radiolabeled Autologous 35-Day-Old Red Blood Cells Prepared With a Modified S-303 Treatment for Pathogen Inactivation.
   Vox Sang 2008;95(Suppl 1):8
3. P Rasongles, F Knutson, O Garraud, R Tardivel, P Schlenke, M Lozano, L Barbolla, M Jacquet, L Lin, L Corash, D Sundin. Results from an Ongoing Hemovigilance Program Utilizing an Electronic Data Capture System to Characterize the Safety Profile of Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).
   Vox Sang 2008;95(Suppl 1):15
4. F Cognasse, JM Payrat, L Corash, JC Osselaer, O Garraud. Platelet Components Associated with Acute Transfusion Reactions: The Role of Platelet-Derived Soluble CD40-Ligand.
   Vox Sang 2008;95(Suppl 1):51
5. F Cognasse, JM Payrat, L Corash, JC Osselaer, O Garraud. Platelet Components Associated with Soluble CD40 Ligand-Associated Acute Transfusion Reactions: The Role of Pathogen Inactivation by Amotosalen.
   Vox Sang 2008;95(Suppl 1):160
6. R Garcia de Villaescusa, ML Ruiz Ayala, A Polo Escriche, MO Pinillos Garcia, F Antonanzas Villar. Pathogen Reduction of Platelets: Limitations of Economic Evaluations.
   Vox Sang 2008;95(Suppl 1):219
7. SJ Wagner, A Skripchenko, A Myrup, H Awatefe, D Thompson-Montgomery, G Moroff, P Carmichael and L Lin. The Effect of Amotosalen Photochemical Treatment (PCT) on the in Vitro Properties of Pooled, Individually-Leukoreduced, Whole Blood-Derived Platelets Stored in 100% Plasma.
   Vox Sang 2008;95(Suppl 1):263
8. JC Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Bosly, JS Lin, and L Corash. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use by Hematology Patients during Three Years of Routine Practice.
   Vox Sang 2008;95(Suppl 1):283
9. JC Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Bosly, JS Lin, and L Corash. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use in a Diverse Patient Population during Three Years of Routine Practice.
   Vox Sang 2008;95(Suppl 1):284
10. H Löf, F Knutson. INTERCEPT Technology Reduces the Number of Side Effects after Platelet Transfusions.
    Vox Sang 2008;95(Suppl 1):286
11. L Infanti, S Job, M Santoro, T Silzle, M Rüesch, C Stebler, J Halter, D Sundin, M Propst, L Lin, L Corash, A Gratwohl. Platelet Components Treated with Pathogen Inactivation using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Observational Trial in Switzerland.
    Vox Sang 2008;95(Suppl 1):289
12. JC Osselaer, C Doyen, L Defoin, S Vandenbossche, C Debry, M Goffaux, N Messe, M Van Hooydonk, L Corash, and L Lin. Impact of Amotosalen Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System) on the Response to Transfusion with 6- and 7-day Old Components.
    Vox Sang 2008;95(Suppl 1):291
13. MF Angelini-Tibert, P Simon, C Currie, L Corash, D Sundin, L Lin, P Rasonglès. Safety of Transfusing Split Platelet Components Prepared with Amotosalen Photochemical Treatment During a Chikungunya Virus Epidemic.
    Vox Sang 2008;95(Suppl 1):293
14. L Sawyer, L Pinkoski, M Deane, T Peterson and P Carmichael. Storage of INTERCEPT-Treated Double Dose Platelets in Two Containers.
    Vox Sang 2008;95(Suppl 1):299
15. L Sawyer, R Mababangloob, N Patel, J Kinsey and D Hanson. Pathogen Inactivation Achieved in Platelets Suspended in Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol.
    Vox Sang 2008;95(Suppl 1):299-300
16. J C Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, J Kerger, J S Lin, and L Corash. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use by Oncology Patients during Three Years of Routine Practice.
    Vox Sang 2008;95(Suppl 1):300
17. L Corash, J S Lin, J Eiden. Acute Lung Injury in Patients Receiving Repeated Platelet Transfusions.
    Vox Sang 2008;95(Suppl 1):300-301
18. A Brussel, A Vandercappellen, L Lin, M Steiert. Evaluation of Viral and Bacterial Inactivation in Platelet Concentrates Suspended In 100% Plasma Treated with the INTERCEPT Blood System.
    Vox Sang 2008;95(Suppl 1):301
19. D Kientz, H Isola, ML Wiesel, M Laforet, F Bigey, JP Cazenave. Validation of Apheresis Concentrated Platelet Collection in Additive Solution with the MCS+ Device, for Pathogenic Inactivation with the Amotosalen Photochemical Process and UVA Light.
    Vox Sang 2008;95(Suppl 1):307
20. JP Cazenave, C Waller, I Mendel, D Kientz, G Kandel, JP Raidot, ML Wiesel, M Laforet, H Isola. Clinical Experience with Conventional Versus INTERCEPT Platelet Concentrates Transfused to all Patients During Two One-Year Periods: Reduction of Adverse Events with Equivalent Use of Blood Products.
    Vox Sang 2008;95(Suppl 1):305-306
21. JP Cazenave, ML Wiesel, I Mendel, D Kientz, A Faradji, S Mangeant, B Perricard. Intensive and Successful Transfusion of Pathogen Inactivated INTERCEPT Platelet Concentrates for Major Gynecological and Obstetrical Surgery in Glanzmann Thrombasthenia Type 1 with the Gypsy Mutation.
    Vox Sang 2008;95(Suppl 1):306
22. R Henschler, M Wiesneth, HU Pfeiffer, M Mueller, L Lin, L Corash, E Seifried. Generation of Double Dose Platelet Concentrates from Pooled Buffy-Coats for Pathogen Inactivation with INTERCEPT.
    Vox Sang 2008;95(Suppl 1):315
23. M Steiert, E Castro, P Grellier, J Benach, WC Van Voorhis, RT Eastman, K Dupuis, L Sawyer, L Lin. Photochemical Inactivation with Amotosalen and UVA Light of Protozoan Parasites in Platelet and Plasma Components Using INTERCEPT Blood System.
    Vox Sang 2008;95(Suppl 1):291
24. K Dupuis and L Sawyer. Inactivation of Influenza Virus Type A H5N1 in Platelets and Plasma by Treatment with the INTERCEPT Blood System.
    Vox Sang 2008;95(Suppl 1):301
25. F Knutson, K Lejskog, M Ståhle, O Korsgren. The INTERCEPT Technology as Novel Approach for the Generation of Pathogen Inactivated Serum for the Culturing of Pancreatic Islets: Opportunities for Improvements.
    Vox Sang 2008;95(Suppl 1):279
26. L Pinkoski, T Peterson, J Bayat, L Corash. Coagulation Factor Activity In INTERCEPT Plasma after Storage for 24 Months at -25° C.
    Vox Sang 2008;95(Suppl 1):288
27. A Rapaille, N de Valensart, E Goossenaerts, J Irsch, L Lin, V Deneys. INTERCEPT Treatment for Pathogen Inactivation of Thawed Plasma: Coagulation Factors and Function are Preserved.
    Vox Sang 2008;95(Suppl 1):292
28. N de Valensart, A Rapaille, E Goossenaerts, J Irsch, L Lin, V Deneys. Analysis of the Impact of INTERCEPT Treatment on Fresh Plasma: Preservation of Coagulation Factors and Inhibitors Functional Activity.
    Vox Sang 2008;95(Suppl 1):293
29. JC Osselaer, L Defoin, M Goffaux, M Vandendaele, L Lin, E Goossenaerts, P Carmichael. Routine Production of Three Plasma Products from One INTERCEPT Blood System Treatment.
    Vox Sang 2008;95(Suppl 1):294
30. JP Cazenave, JC Osselaer, C Waller, M Jacquet, L Lin, L Corash, and D Sundin. Results from an Ongoing Hemovigilance Program Using an Electronic Data Capture System to Characterize the Safety Profile of Plasma Transfusions Prepared with the INTERCEPT Blood System.
    Vox Sang 2008;95(Suppl 1):296
31. JP Cazenave, P Netzer, C Ravanat, A Boucher, H Isola, D Kientz, C Gachet, ML Wiesel. Thrombin Generation Capacity of Therapeutic Apheresis Plasma is Maintained Following Pathogen Inactivation with Photochemical Treatment (INTERCEPT Blood System).
    Vox Sang 2008;95(Suppl 1):306
32. H Isola, D Kientz, F Bigey, C Waller, M Laforet, ML Wiesel, JP Cazenave. Implementation of Pathogen Inactivated Therapeutic Apheresis Plasma Following Photochemical Treatment with INTERCEPT by EFS-Alsace, a French Regional Blood Center.
    Vox Sang 2008;95(Suppl 1):306-307
33. M Naegelen, H Isola, P Morel, JP Cazenave. Impact on Organization of Production of Inactivated Therapeutic Plasma with Two Photochemical Treatments, Methylene Blue or Amotosalen, in Two French Regional Blood Centers.
    Vox Sang 2008;95(Suppl 1):309
34. AC Erickson, MA Schott, VA Lee, J Bayat, GM Castro, MR Clark, AK North, N Mufti and LM Corash. Characterization of RBC Dehydration Induced by Alkaline pH and Glutathione.
    Vox Sang 2008;95(Suppl 1):304